Table 2: Cytotoxicity of 1,3-diphenylpyrazole-chromenoquinolin-6-one compounds (5a‒ad) on selected human cancer cell lines.
|
|
Compound |
|
|
|
|
|
IC50 values (µM) a |
|
|
|
|
||||
|
|
|
|
A549b |
|
|
MCF-7c |
|
|
HeLad |
|
|
DU-145e |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
5a |
21.26 ± 1.08 |
|
9.91 ± 0.55 |
|
22.38 ± 1.55 |
|
18.32 ± 0.88 |
|
|
|||||
|
|
5b |
26.91 ± 1.92 |
|
8.20 ± 0.42 |
|
22.96 ± 1.32 |
|
17.51 ± 0.92 |
|
|
|||||
|
|
5c |
32.35 ± 1.86 |
|
10.73± 0.34 |
|
39.90 ± 2.22 |
|
21.85 ± 0.86 |
|
|
|||||
|
|
5d |
50.11 ± 2.78 |
|
15.27 ± 0.46 |
|
62.57 ± 3.96 |
|
30.85 ± 1.78 |
|
|
|||||
|
|
5e |
6.46 ± 0.99 |
|
5.46 ± 0.51 |
|
14.79 ± 2.02 |
|
6.31 ± 0.99 |
|
|
|||||
|
|
5f |
10.81 ± 0.63 |
|
1.98 ± 0.71 |
|
3.23 ± 0.22 |
|
4.69 ± 0.63 |
|
|
|||||
|
|
5g |
11.32 ± 0.89 |
|
3.68 ± 0.91 |
|
14.12 ± 1.02 |
|
6.53 ± 0.89 |
|
|
|||||
|
|
5h |
25.50 ± 1.54 |
|
11.70 ± 0.61 |
|
25.11 ± 1.86 |
|
18.01 ± 1.54 |
|
|
|||||
|
|
5i |
19.66 ± 0.98 |
|
5.02 ± 0.71 |
|
18.38 ± 1.04 |
|
10.78 ± 0.98 |
|
|
|||||
|
|
5j |
15.55 ± 1.52 |
|
1.82 ± 0.24 |
|
4.68 ± 0.31 |
|
6.84 ± 0.52 |
|
|
|||||
|
|
5k |
15.24 ± 1.26 |
|
4.68 ± 0.46 |
|
18.72 ± 1.02 |
|
9.14± 1.26 |
|
|
|||||
|
|
5l |
16.98 ± 0.52 |
|
3.65 ± 0.23 |
|
15.70 ± 1.03 |
|
6.61 ± 0.52 |
|
|
|||||
|
|
5m |
16.73 ± 1.06 |
|
3.50 ± 0.96 |
|
7.24 ± 0.98 |
|
10.47 ± 1.86 |
|
|
|||||
|
|
5n |
39.81 ± 2.05 |
|
12.56 ± 1.66 |
|
19.67 ±1.96 |
|
21.92 ± 1.26 |
|
|
|||||
|
|
5o |
24.83 ± 1.52 |
|
17.17 ± 1.03 |
|
19.61 ± 2.02 |
|
20.18 ± 0.64 |
|
|
|||||
|
|
5p |
14.21 ± 1.29 |
|
11.81 ± 0.94 |
|
21.72 ± 1.03 |
|
11.22 ± 1.69 |
|
|
|||||
|
|
5q |
13.30 ± 1.38 |
|
2.75 ± 0.54 |
|
4.26 ± 0.76 |
|
6.18 ± 0.96 |
|
|
|||||
|
|
5r |
15.88 ± 1.62 |
|
2.80 ± 0.84 |
|
4.36 ± 0.12 |
|
6.92 ± 0.47 |
|
|
|||||
|
|
5s |
10.59 ± 0.43 |
|
1.22 ± 0.94 |
|
3.51 ± 0.13 |
|
2.99 ± 0.13 |
|
|
|||||
|
|
5t |
5.25 ± 0.23 |
|
1.64 ± 0.76 |
|
2.71 ± 0.33 |
|
4.52 ± 0.37 |
|
|
|||||
|
|
5u |
19.05 ± 2.69 |
|
11.41 ± 0.52 |
|
17.37 ± 0.02 |
|
13.58 ± 2.69 |
|
|
|||||
|
|
5v |
17.11 ± 1.36 |
|
3.23 ± 0.98 |
|
10.56 ± 0.41 |
|
7.49 ± 0.76 |
|
|
|||||
|
|
5w |
21.00 ± 1.65 |
|
9.75 ± 0.33 |
|
16.18 ± 0.66 |
|
15.89 ± 1.65 |
|
|
|||||
|
|
5x |
15.88 ± 1.20 |
|
2.81 ± 0.87 |
|
4.36 ± 0.53 |
|
6.92 ± 0.60 |
|
|
|||||
|
|
5y |
11.35 ± 1.23 |
|
9.53 ± 0.91 |
|
23.77± 1.89 |
|
10.30 ± 1.23 |
|
|
|||||
|
|
5z |
26.30 ± 2.36 |
|
13.92 ± 0.78 |
|
24.85 ± 2.49 |
|
19.56 ± 1.36 |
|
|
|||||
|
|
5aa |
28.84 ± 2.13 |
|
20.14 ± 1.02 |
|
26.91 ± 1.26 |
|
22.40 ± 1.73 |
|
|
|||||
|
|
5ab |
17.37 ± 0.95 |
|
12.73 ± 0.51 |
|
16.87 ± 1.23 |
|
14.12 ± 0.61 |
|
|
|||||
|
|
5ac |
17.78 ± 1.05 |
|
13.66 ± 1.56 |
|
21.18 ± 2.01 |
|
17.00 ± 1.05 |
|
|
|||||
|
|
5ad |
20.41 ± 0.92 |
|
12.30 ± 1.32 |
|
20.46 ± 1.36 |
|
18.31 ± 0.76 |
|
|
|||||
|
|
Doxorubicin |
1.24 ± 0.59 |
|
1.32 ± 0.11 |
|
1.53 ± 0.47 |
|
2.11 ± 0.70 |
|
|
|||||
|
|
(Positive control) |
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
a 50% Inhibitory concentration after 48 h of drug treatment and the values are average of three individual experiments; bHuman lung cancer; cHuman breast cancer; dHuman cervical cancer; dHuman prostate cancer.